Medication info

Metformin XR Tablets 500mg (Metformin Hydrochloride)

Prescription medicationTabletOralExpired
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Daewoo Pharmaceutical Co., Ltd.
Appearance
White, biconvex, rectangular extended-release tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Expired

MFDS item code 201906867 · Approved 2019.09.26

This product's status changed to Expired on 2024.09.26. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on therapeutic response and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is one 500mg extended-release metformin hydrochloride tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking 2000mg or more per day of immediate-release metformin tablets. - At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess the response to this medicine and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Daewoo Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes with insufficient blood glucose control
View approved original text

This medication is used to treat patients with type 2 diabetes who do not have sufficient blood glucose control with diet and exercise alone, especially overweight adults. It can be used alone or in combination with other oral hypoglycemic agents or insulin to effectively control blood glucose levels. This helps improve blood sugar management and prevents complications.

How to take

Adult dose

The dose should be determined individually based on therapeutic response and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is one 500mg extended-release metformin hydrochloride tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking 2000mg or more per day of immediate-release metformin tablets. - At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess the response to this medicine and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this medicine should be discontinued immediately.

Precautions

This medication can rarely cause a serious condition known as lactic acidosis. Lactic acidosis is a state in which lactic acid accumulates excessively in the body, potentially leading to death if severe, so caution is required. Also, when this drug is used in conjunction with insulin or sulfonylureas, there is a risk of hypoglycemia, so blood glucose levels should be monitored carefully. Patients with moderate to severe renal impairment, dehydration, severe infections, or acute heart disease should not use this medication. In particular, patients with very poor renal function may be at risk from this medication. This medication should be temporarily discontinued before and after procedures using radiologic contrast agents, and can only be resumed once renal function is confirmed to be normal. Patients with allergies to the components of this drug, as well as those with type 1 diabetes, severe metabolic acidosis, or acute heart failure, should not take it. Patients scheduled for surgery should stop taking this medication 48 hours prior to the surgery and can only restart it after kidney function has recovered post-surgery. Patients with poor nutritional status or liver dysfunction, as well as those who consume excessive alcohol, have an increased risk of lactic acidosis and should take caution. While taking this medication, kidney function should be monitored regularly, and particularly elderly patients or those with slightly reduced kidney function should be monitored more frequently. Gastrointestinal symptoms (nausea, vomiting, diarrhea, etc.) are common, but most improve over time. If symptoms are severe, consult a physician. If symptoms such as sudden weakness, shortness of breath, muscle pain, or abdominal pain occur while taking this medication, inform medical personnel immediately, as this may be an early sign of lactic acidosis. Caution is also needed if blood glucose control is poor or if hypoglycemic symptoms appear, particularly when taken with other hypoglycemic agents, as the risk of hypoglycemia increases. During pregnancy, this medication should be used cautiously, considering the effects on the fetus, and during lactation, it is advisable to consult a doctor about either discontinuing breastfeeding or the medication. It is not recommended for children, as safety and efficacy have not been established, and elderly patients should adjust the dosage according to their kidney function. In case of overdose, hypoglycemia is rare, but there is a risk of lactic acidosis, so immediate treatment at a hospital is necessary; blood dialysis may be required. This medication can interact with other drugs, so if you are taking any other medications, you must inform your doctor or pharmacist. Finally, this medication should only be taken according to a doctor's prescription and instructions, and should not be stopped or changed arbitrarily.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste alteration
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It should be kept at room temperature between 1°C and 30°C, avoiding extremely hot or cold places.

Appearance and packaging

Appearance

White, biconvex, rectangular extended-release tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.